BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
Key Highlights
- ➤BridgeBio (BBIO) launches nationwide ATTR-CM education effort with community partners
- ➤October 6 YouTube premiere anchors programming ahead of World Amyloidosis Day October 26
- ➤Community partners will support viewings and education at 40 locations nationwide
- ➤Approximately 1 in 25 Black Americans carries an ATTR-CM-associated genetic variant
- ➤Effort targets earlier ATTR-CM recognition among Black Americans and healthcare professionals
Expert Statements
Kevin Kwaku, M.D., Ph.D., President of the Association of Black Cardiologists
“ATTR-CM deserves greater attention as part of the cardiovascular health conversation, particularly for Black Americans who may be at increased risk. We’re proud to support BridgeBio in helping patients, families and healthcare professionals recognize when there may be more to a heart failure diagnosis”
Uma Sinha, Ph.D., Chief Scientific Officer at BridgeBio
“Approximately 1 in 25 Black Americans carries a genetic variant associated with ATTR-CM, and too often the diagnosis comes only after the heart has already been significantly affected”
Uma Sinha, Ph.D., Chief Scientific Officer at BridgeBio
“Our understanding of this progressive disease has moved faster than awareness of it. Shortness of breath, fatigue, and carpal tunnel in both wrists can be written off as aging or as a more common form of heart failure, and years can pass before anyone names the real cause. Putting clinicians, cultural leaders and Howard ‘H’ White’s lived experience in the same room, alongside partners rooted in these communities, is how we close this gap.”
Olajide Williams, M.D., M.S., Founder and Board Chair of Hip Hop Public Health
“At Hip Hop Public Health, we know that people are more likely to engage with health information when it is relevant to their lives and delivered through voices and cultural touchpoints they trust. Our goal is to make these conversations accessible and actionable, so people feel empowered to recognize changes in their health, ask questions and advocate for themselves and their families”
Albert J. Hicks III, M.D., MPH, Director of Cardiopulmonary Care and Heart/Lung Transplant at Integris Baptist Medical Center in Oklahoma
“ATTR-CM can hide in plain sight because its symptoms often mirror heart failure we see every day. For Black patients, particularly those with ancestry-linked risk, knowing when to look beyond the familiar diagnosis can change the course of the disease”
- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide
PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company” or “BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases, today announced a nationwide education effort with community partners to increase awareness of transthyretin amyloid cardiomyopathy, also called ATTR cardiac amyloidosis (ATTR-CM). ATTR-CM is an underrecognized cause of heart failure that occurs when TTR, a protein that plays an essential role in the transport of vitamin A and thyroxine, becomes unstable, breaks down and builds up in the heart, causing it to become thicker and stiffer and making it harder to pump blood effectively. Because symptoms may resemble more common heart conditions or be dismissed as normal aging, ATTR-CM can be overlooked or identified later in the disease journey.
Get started
Create a free account to read the full story.